Clinical Trials Logo

Clinical Trial Summary

NMDA receptor encephalitis is a rare neurological autoimmune disease with severe neuropsychiatric symptoms, but a typically good functional neurological outcome. The majority of patients experience long-term cognitive, psychological and social impairments that have significant consequences for their well-being and quality of life. However, as the disease was only recently discovered (Dalmau and al. Annals of neurology, 2007), this psycho-social impact has not been studied systematically and the resulting consequences for patients are not adequately appreciated. The proposed study aims at characterizing the cognitive and psycho-social long-term consequences of this rare disease. Our main hypothesis is that NMDAR encephalitis has a persistent and clinically relevant impact on the patients' long-term cognitive, psychological and social well-being. Furthermore, we hypothesize that longterm subjective outcomes depend on both internal and external factors, such as acute disease course, access to post-acute care, caregiver support, personal coping strategies, or access to health education resources and peer group support.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  • Autoimmune Diseases of the Nervous System
  • Encephalitis

NCT number NCT05954468
Study type Observational
Source Hospices Civils de Lyon
Contact HONNORAT Jérôme, Pr
Phone 04 72 35 78 06
Email jerome.honnorat@chu-lyon.fr
Status Recruiting
Phase
Start date October 9, 2023
Completion date October 9, 2024